LV11103B - Oraly administerable drugs for the treatment of central dopamine deficiency conditions - Google Patents

Oraly administerable drugs for the treatment of central dopamine deficiency conditions Download PDF

Info

Publication number: LV11103B
Authority: LV; Latvia
Prior art keywords: weight; polyvinyl alcohol; parts; von; pva
Prior art date: 1991-01-23

Application number

LVP-93-567A

Other languages

English (en)

Latvian (lv)

Other versions

LV11103A (lv

Inventor

Udo Prof Dr Wenzel

Guenther Dipl Ing Weber

Juergen Dr Metzner

Alfred Dr Daerr

Sabine Dr Freitag

Frank-Ulrich Dr Floether

Frank-Michael Albert

Margit Dr Haase

Edith Leistner

Original Assignee

Isis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-23

Filing date

1993-06-14

Publication date

1996-06-20

1993-06-14 Application filed by Isis Pharma Gmbh filed Critical Isis Pharma Gmbh

1996-04-20 Publication of LV11103A publication Critical patent/LV11103A/xx

1996-06-20 Publication of LV11103B publication Critical patent/LV11103B/lv

Links

229940079593 drug Drugs 0.000 title claims abstract description 6
239000003814 drug Substances 0.000 title claims abstract description 5
230000007812 deficiency Effects 0.000 title claims abstract 3
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title abstract description 7
229960003638 dopamine Drugs 0.000 title abstract description 4
239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 54
229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 54
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 13
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 13
229960004502 levodopa Drugs 0.000 claims abstract description 13
229960004205 carbidopa Drugs 0.000 claims abstract description 11
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims abstract description 11
229920002959 polymer blend Polymers 0.000 claims abstract 6
239000011148 porous material Substances 0.000 claims abstract 3
239000000203 mixture Substances 0.000 claims abstract 2
235000019422 polyvinyl alcohol Nutrition 0.000 claims description 52
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 13
238000000034 method Methods 0.000 claims description 6
238000002360 preparation method Methods 0.000 claims description 2
230000007062 hydrolysis Effects 0.000 claims 2
238000006460 hydrolysis reaction Methods 0.000 claims 2
239000000546 pharmaceutical excipient Substances 0.000 claims 2
210000003169 central nervous system Anatomy 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
239000006186 oral dosage form Substances 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 2
239000002671 adjuvant Substances 0.000 abstract 1
239000013583 drug formulation Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229940068984 polyvinyl alcohol Drugs 0.000 description 18
229940117958 vinyl acetate Drugs 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 6
239000000499 gel Substances 0.000 description 6
235000019359 magnesium stearate Nutrition 0.000 description 4
GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000000243 solution Substances 0.000 description 3
208000018737 Parkinson disease Diseases 0.000 description 2
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
210000002268 wool Anatomy 0.000 description 2
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
NUFNQYOELLVIPL-UHFFFAOYSA-N acifluorfen Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(OC=2C(=CC(=CC=2)C(F)(F)F)Cl)=C1 NUFNQYOELLVIPL-UHFFFAOYSA-N 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000012267 brine Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000001653 corpus striatum Anatomy 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
238000004898 kneading Methods 0.000 description 1
239000004571 lime Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

LVP-93-567A 1991-01-23 1993-06-14 Oraly administerable drugs for the treatment of central dopamine deficiency conditions LV11103B (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE4101873A DE4101873C2 (de)	1991-01-23	1991-01-23	Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
PCT/DE1992/000043 WO1992012710A1 (fr)	1991-01-23	1992-01-23	Formule de medicament a administration orale pour le traitement des insuffisances en dopamine du systeme nerveux central

Publications (2)

Publication Number	Publication Date
LV11103A LV11103A (lv)	1996-04-20
LV11103B true LV11103B (en)	1996-06-20

Family

ID=6423528

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-93-567A LV11103B (en)	1991-01-23	1993-06-14	Oraly administerable drugs for the treatment of central dopamine deficiency conditions

Country Status (22)

Country	Link
US (1)	US5532274A (fr)
EP (1)	EP0568577B1 (fr)
JP (1)	JP3382940B2 (fr)
AT (1)	ATE147264T1 (fr)
AU (1)	AU658171B2 (fr)
BG (1)	BG61677B1 (fr)
CA (1)	CA2101164C (fr)
CZ (1)	CZ280847B6 (fr)
DE (2)	DE4101873C2 (fr)
DK (1)	DK0568577T3 (fr)
EE (1)	EE03016B1 (fr)
ES (1)	ES2098496T3 (fr)
FI (1)	FI101040B (fr)
GR (1)	GR3022993T3 (fr)
LT (1)	LT3659B (fr)
LV (1)	LV11103B (fr)
NO (1)	NO304638B1 (fr)
RO (1)	RO114737B1 (fr)
RU (1)	RU2114619C1 (fr)
SK (1)	SK278736B6 (fr)
UA (1)	UA27848C2 (fr)
WO (1)	WO1992012710A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6756056B2 (en) *	1997-04-08	2004-06-29	Alan A. Rubin	Treatment of Parkinson's disease and related disorders by novel formulations of the combination carbidopa-levodopa
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
RU2173150C1 (ru) *	2000-06-27	2001-09-10	Васильев Виталий Николаевич	Фармацевтическая композиция для биокоррекции симпатико-адреналовой системы
US6531153B2 (en)	2001-05-29	2003-03-11	Drugtech Corporation	Composition with sustained release of levodopa and carbidopa
NZ532096A (en) *	2001-09-28	2006-10-27	Mcneil Ppc Inc	Dosage forms having an inner core and outer shell with different shapes
KR20050083750A (ko) *	2002-10-11	2005-08-26	디포메드 디벨롭먼트 리미티드	위-체류성 레보도파 전달 형태
ES2360759T3 (es) *	2003-08-29	2011-06-08	Centocor Ortho Biotech Inc.	Composiciones farmacéuticas y procedimiento de utilización de la levodopa y de la carbidopa.
DE602004031134D1 (de)	2003-08-29	2011-03-03	Transform Pharmaceuticals Inc	Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US8815950B2 (en) *	2003-08-29	2014-08-26	Janssen Biotech, Inc.	Pharmaceutical compositions and method of using levodopa and carbidopa
PT1751087E (pt) *	2004-06-04	2012-09-10	Xenoport Inc	Derivados de levodopa e as suas composições e utilizações
MX2007011976A (es) *	2005-03-28	2007-12-07	Orexo Ab	Composiciones farmaceuticas novedosas utiles en el tratamiento de la enfermedad de parkinson.
CA2613631A1 (fr) *	2005-06-23	2007-01-04	Spherics, Inc.	Formes de dosage ameliorees pour le traitement de troubles moteurs
AR055106A1 (es) *	2005-08-05	2007-08-08	Osmotica Pharmaceutical Argent	Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
AU2007338631A1 (en) *	2006-12-22	2008-07-03	Combinatorx, Incorporated	Pharmaceutical compositions for treatment of parkinson's disease and related disorders
CN101910113A (zh)	2007-12-28	2010-12-08	怡百克制药公司	左旋多巴控释制剂及其用途
EP2233131A1 (fr) *	2009-03-23	2010-09-29	Laboratorios Lesvi, S.L.	Composition pharmaceutique contenant de la lévodopa, un inhibiteur de la catéchol-O-méthyl-transférase et de la carbidopa
KR20130009553A (ko) *	2011-07-15	2013-01-23	한미약품 주식회사	몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
US10987313B2 (en)	2013-10-07	2021-04-27	Impax Laboratories, Llc	Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh)	2013-10-07	2016-06-08	怡百克制药公司	左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
JP7066351B2 (ja) *	2017-08-18	2022-05-13	大原薬品工業株式会社	良好な徐放性を有する、レボドパ含有小型化錠剤
JP6695013B1 (ja) *	2018-11-13	2020-05-20	日本酢ビ・ポバール株式会社	結合剤
ES3033908T3 (en) *	2018-11-13	2025-08-11	Japan Vam & Poval Co Ltd	Bonding agent
EP4134103A4 (fr) *	2020-04-10	2024-04-24	Japan Vam & Poval Co., Ltd.	Liant
US20230405531A1 (en) *	2020-11-19	2023-12-21	Asahi Kasei Kabushiki Kaisha	Porous membrane
US11986449B2 (en)	2020-12-22	2024-05-21	Amneal Pharmaceuticals Llc	Levodopa dosing regimen
KR20230124622A (ko)	2020-12-22	2023-08-25	암닐 파마슈티컬스 엘엘씨	레보도파 투여 요법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE631201C (de) *	1932-08-07	1936-06-16	Chemische Forschungs Gmbh	Traegerstoff fuer Arzneimittel
DE748317C (de) *	1941-08-17	1944-12-19	Wacker Chemie Gmbh	Verfahren zur Herstellung in Wasser zerfallender Faeden, Filme, Baender, Schlaeuche u. dgl. aus unvollstaendig verseiften Polyvinylalkoholen
US3584113A (en) *	1967-08-31	1971-06-08	Eisai Co Ltd	Process for the production of medical preparations having sustained release of therapeutical effect
NL149372B (nl) *	1968-10-01	1976-05-17	Merck & Co Inc	Werkwijze voor het bereiden van farmaceutische preparaten, alsmede de door toepassing daarvan verkregen gevormde voortbrengselen.
US3769424A (en) *	1970-10-01	1973-10-30	Merck & Co Inc	Composition and method of treating dopamine deficiency in brain tissue
IE49522B1 (en)	1979-04-26	1985-10-16	Merrell Toraude & Co	Alpha-halomethylaminoacids
DE3042916A1 (de) *	1979-06-01	1982-07-01	Joachim 7440 Nürtingen Dudzik	Tablette
CA1218604A (fr) *	1981-07-08	1987-03-03	Alec D. Keith	Vehicules de trinitroglycerol a decharge temporisee, et leurs domaines d'emploi
CH652025A5 (de) *	1981-09-14	1985-10-31	Hoffmann La Roche	Pharmazeutisches praeparat.
US4424235A (en) *	1981-09-14	1984-01-03	Hoffmann-La Roche Inc.	Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS5852219A (ja) *	1981-09-22	1983-03-28	Sumitomo Chem Co Ltd	パ−キンソン病治療剤
EP0147780A3 (fr) *	1984-01-03	1987-03-11	Merck & Co. Inc.	Dispositif pour la libération d'un médicament
US4927633A (en) *	1984-03-19	1990-05-22	Alza Corporation	Dispenser for delivering drug to livestock
US4685918A (en) *	1985-02-01	1987-08-11	Merck & Co., Inc.	Lipid osmotic pump
NZ220599A (en) *	1986-06-16	1990-10-26	Merck & Co Inc	Controlled release oral dosage formulation of carbidopa and levodopa
US4832957A (en) *	1987-12-11	1989-05-23	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
US4983400A (en) *	1986-06-16	1991-01-08	Merck & Co., Inc.	Controlled release combination of carbidopa/levodopa
ZA889189B (en) *	1986-06-16	1989-08-30	Merck & Co Inc	Controlled release combination of carbidopa/levodopa
SE460947B (sv) *	1986-08-26	1989-12-11	Lejus Medical Ab	En multiple-unit-dos komposition av l-dopa
US4892778A (en) *	1987-05-27	1990-01-09	Alza Corporation	Juxtaposed laminated arrangement
US4940465A (en) *	1987-05-27	1990-07-10	Felix Theeuwes	Dispenser comprising displaceable matrix with solid state properties
US4915949A (en) *	1987-07-13	1990-04-10	Alza Corporation	Dispenser with movable matrix comprising a plurality of tiny pills
CA1331563C (fr) *	1987-08-03	1994-08-23	Gaylen M. Zentner	Systeme de liberation controlee de medicaments avec modulation de type donnan par des resines chargees insolubles
US4946686A (en) *	1987-09-24	1990-08-07	Merck & Co., Inc.	Solubility modulated drug delivery system
AU608891B2 (en) *	1987-09-24	1991-04-18	Merck & Co., Inc.	Solubility modulated drug delivery device
DE3841955A1 (de) *	1987-12-31	1989-07-13	Asta Pharma Ag	Synergistische kombination von decarboxylasehemmern und l-dopa-pellets
DE3875716D1 (de) *	1987-12-31	1992-12-10	Asta Medica Ag	Synergistische kombination von decarboxylasehemmern und l-dopa-pellets.

1991
- 1991-01-23 DE DE4101873A patent/DE4101873C2/de not_active Expired - Lifetime
1992
- 1992-01-23 SK SK3692-92A patent/SK278736B6/sk unknown
- 1992-01-23 JP JP50323992A patent/JP3382940B2/ja not_active Expired - Lifetime
- 1992-01-23 RU RU93051537/14A patent/RU2114619C1/ru not_active IP Right Cessation
- 1992-01-23 CA CA002101164A patent/CA2101164C/fr not_active Expired - Fee Related
- 1992-01-23 AU AU11868/92A patent/AU658171B2/en not_active Ceased
- 1992-01-23 AT AT92903405T patent/ATE147264T1/de not_active IP Right Cessation
- 1992-01-23 RO RO93-01024A patent/RO114737B1/ro unknown
- 1992-01-23 DK DK92903405.6T patent/DK0568577T3/da active
- 1992-01-23 UA UA94051480A patent/UA27848C2/uk unknown
- 1992-01-23 ES ES92903405T patent/ES2098496T3/es not_active Expired - Lifetime
- 1992-01-23 DE DE59207852T patent/DE59207852D1/de not_active Expired - Lifetime
- 1992-01-23 US US08/090,163 patent/US5532274A/en not_active Expired - Lifetime
- 1992-01-23 CZ CS923692A patent/CZ280847B6/cs unknown
- 1992-01-23 EP EP92903405A patent/EP0568577B1/fr not_active Expired - Lifetime
- 1992-01-23 WO PCT/DE1992/000043 patent/WO1992012710A1/fr not_active Ceased
1993
- 1993-05-14 LT LTIP555A patent/LT3659B/lt not_active IP Right Cessation
- 1993-06-14 LV LVP-93-567A patent/LV11103B/lv unknown
- 1993-06-22 BG BG97894A patent/BG61677B1/bg unknown
- 1993-07-09 NO NO932159A patent/NO304638B1/no not_active IP Right Cessation
- 1993-07-22 FI FI933304A patent/FI101040B/fi active
1994
- 1994-06-29 EE EE9400066A patent/EE03016B1/xx not_active IP Right Cessation
1997
- 1997-04-01 GR GR970400667T patent/GR3022993T3/el unknown

Also Published As

Publication number	Publication date
CA2101164A1 (fr)	1992-07-24
SK369292A3 (en)	1998-02-04
LV11103A (lv)	1996-04-20
LTIP555A (en)	1994-11-25
SK278736B6 (sk)	1998-02-04
NO932522L (no)	1993-07-09
EP0568577A1 (fr)	1993-11-10
EP0568577B1 (fr)	1997-01-08
AU1186892A (en)	1992-08-27
CA2101164C (fr)	2001-04-24
ATE147264T1 (de)	1997-01-15
DK0568577T3 (da)	1997-06-30
DE4101873C2 (de)	1993-12-09
JP3382940B2 (ja)	2003-03-04
CZ369292A3 (en)	1993-09-15
CZ280847B6 (cs)	1996-04-17
DE4101873A1 (de)	1992-07-30
UA27848C2 (uk)	2000-10-16
FI101040B (fi)	1998-04-15
BG97894A (bg)	1994-04-29
DE59207852D1 (de)	1997-02-20
NO304638B1 (no)	1999-01-25
BG61677B1 (bg)	1998-03-31
AU658171B2 (en)	1995-04-06
NO932522D0 (no)	1993-07-09
EE03016B1 (et)	1997-08-15
RU2114619C1 (ru)	1998-07-10
RO114737B1 (ro)	1999-07-30
LT3659B (en)	1996-01-25
JPH06504543A (ja)	1994-05-26
GR3022993T3 (en)	1997-07-30
FI933304A0 (fi)	1993-07-22
US5532274A (en)	1996-07-02
FI933304L (fi)	1993-07-22
ES2098496T3 (es)	1997-05-01
WO1992012710A1 (fr)	1992-08-06

Publication	Publication Date	Title
LV11103B (en)	1996-06-20	Oraly administerable drugs for the treatment of central dopamine deficiency conditions
DE69821553T2 (de)	2004-12-23	Granulatzubereitung enthaltend Simethicon und granuliertes wasserfreies Calciumphosphat
DE69916922T2 (de)	2006-11-23	Ibuprofenhaltige Arzneizubereitung
DE69217191T2 (de)	1997-08-28	Multipartikel-tablette mit schnellauflösbarkeit
DE69318415T2 (de)	1998-09-03	Arzneitablette, die befähigt ist, einen oder mehrere wirkstoffe mit unterschiedlichen abgaberaten freizusetzen
DE69825165T2 (de)	2005-07-14	Arzneimittelform mit zwei überzugs-schichten
DE69112841T2 (de)	1996-04-04	Direktverpressbarer xylit sowie verfahren.
DE1492107C3 (de)	1973-12-06	Verfahren zur Herstellung einer Acetylsalicylsauretablette
DE69315257T2 (de)	1998-05-14	Simethicon enthaltende Arzneimittel zur Behandlung gastrointestinaler Störungen
DE69230112T2 (de)	2000-03-02	Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
DE69313983T2 (de)	1998-02-19	Ein Guanidinothiazol und Antazida enthaltende Arzneimittel
DE69620606T2 (de)	2002-10-24	Feste oral anzuwendende arzeneiform
EP1110544B1 (fr)	2008-02-13	Méthode pour fabriquer une préparation orale masquant le goût
DE69518820T2 (de)	2001-02-22	Rotogranulat und Beschichtung von Acetaminophen, Pseudoephedrin, Chlorpheniramin und, gegebenenfalls, Dextromethorphan
EP1165081B1 (fr)	2005-05-25	Procede de preparation de compositions pharmaceutiques de tolperisone pour administration orale
EP3634379B1 (fr)	2024-08-28	Pastille en mousse à décomposition rapide, présentant un poids surfacique élevé
EP1001757A1 (fr)	2000-05-24	Antalgique d'action rapide
CH655241A5 (de)	1986-04-15	Verfahren zur herstellung therapeutisch wirksamer praeparate mit anhaltendem verlauf der wirkstoff-freisetzung.
AT5350U1 (de)	2002-06-25	Medikament zur oralen verabreichung
JPH10147517A (ja)	1998-06-02	高められた崩壊特性を有するフイルムコーテイングされた錠剤組成物
DE1667888B2 (de)	1977-11-10	Langwirkende geformte pharmazeutische zubereitungen
EP1140013B1 (fr)	2003-09-17	Comprimes antiacides generant des suspensions moussantes
EP0471967B1 (fr)	1996-04-24	Comprimé à mâcher à base de sucralfate
DE69919003T2 (de)	2005-08-04	Acetaminophen-formulierung mit verlängerter freisetzung
DE69635298T2 (de)	2006-07-13	Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen